Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Nuclear Medicine

• Publication date

  2006-04-01

• Fields of study

  Medicine

• Identifiers
  PMID 16595499
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study.

  2006cited by this paper
• OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.

  2005cited by this paper
• Blood and bone marrow dosimetry in radioiodine therapy of differentiated thyroid cancer after stimulation with rhTSH.

  2005cited by this paper
• Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.

  2004cited by this paper
• The radiotoxicity of 131I therapy of thyroid cancer: assessment by micronucleus assay of B lymphocytes.

  2004cited by this paper
• Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma

  2003cited by this paper
• Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.

  2003cited by this paper
• Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.

  2003influential reference
• Increasing efficacy and safety of treatments of patients with well-differentiated thyroid carcinoma by measuring body retentions of 131I.

  2003cited by this paper
• A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation.

  2002cited by this paper
• Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.

  2002cited by this paper
• A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.

  1999cited by this paper
• Estimation of risk based on biological dosimetry for patients treated with radioiodine.

  1999cited by this paper
• SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies.

  1998cited by this paper
• Biologic dosimetry in thyroid cancer patients after repeated treatments with iodine-131.

  1998cited by this paper
• Predictive estimate of blood dose from external counting data preceding radioiodine therapy for thyroid cancer.

  1993cited by this paper
• Absorbed dose calculations to blood and blood vessels for internally deposited radionuclides.

  1991cited by this paper
• Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer.

  1990cited by this paper
• National electrical manufacturers association

  1983cited by this paper
• MIRD Pamphlet #11: S, Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs

  1975cited by this paper
• The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer.

  1962cited by this paper

• Relationship between amino acid transporter activity and radioactive iodine therapy efficacy in differentiated thyroid cancer

  2025cites this paper
• Evaluation of Single Time Point Dosimetry Model for Personalized Radioiodine Therapy in Cancer Patients

  2025cites this paper
• Estimation the Maximum Tolerance Activity of Blood by a Simple Algorithm Method in Pediatric Differentiated Thyroid Cancer Patients Treated With Empirical Radioactive Iodine Dosing Based on Risk Stratification

  2025cites this paper
• The role of the hypothalamic-pituitary-thyroid axis in thyroid cancer.

  2025cites this paper
• Blood and bone marrow dosimetry for thyroid cancer patients prepared with rhTSH injection

  2025cites this paper
• Recombinant TSH Performs as Well as Thyroid Hormone Withdrawal for Iodine-131 Therapy With Dosimetry for Thyroid Cancer

  2025cites this paper
• Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer

  2025cites this paper
• Modelling the In Vivo and Ex Vivo DNA Damage Response after Internal Irradiation of Blood from Patients with Thyroid Cancer

  2024cites this paper
• Theranostics of Thyroid Cancer.

  2024cites this paper
• Assessing effective half-life of I-131 in 39 thyroid cancer patients at Dong Nai General Hospital

  2024cites this paper
• Oldie but Goldie: The Fundamental Role of Radioiodine in the Management of Thyroid Cancer

  2024cites this paper
• Dosimetry of 131I in remnant ablation and metastasis of differentiated thyroid cancer treated with high radioactivities and rhTSH

  2024cites this paper
• Simplified Assessment of Radioiodine Biokinetics for Thyroid Cancer Patients: A Practical Approach Using Continuous External Radiation Monitoring

  2024cites this paper
• First Strike personalized predictive radioiodine prescription for inoperable metastatic differentiated thyroid cancer

  2023influential citation
• MIRD Pamphlet No. 28, Part 1: MIRDcalc—A Software Tool for Medical Internal Radiation Dosimetry

  2023cites this paper
• The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer

  2023cites this paper
• Absorbed dose coefficients for adult thyroid cancer patients undergoing radioiodine therapy

  2023influential citation
• Investigation of the Importance of Applying Various Methods of Calculation in Determining the Blood-Absorbed Dose for Patients with Differentiated Thyroid Carcinoma

  2023cites this paper
• Thyroid Hormone Withdrawal versus Recombinant Human TSH as Preparation for I-131 Therapy in Patients with Metastatic Thyroid Cancer: A Systematic Review and Meta-Analysis

  2023cites this paper
• Cytogenetic Damage Induced by Radioiodine Therapy: A Follow-Up Case Study

  2023cites this paper
• Initial results of the INSPIRE clinical trial—investigating radiation dosimetry for differentiated thyroid cancer patients

  2023cites this paper
• Contact restriction time after common nuclear medicine therapies: spreadsheet implementation based on conservative retention function and individual measurements

  2023cites this paper
• Radiation Safety and External Radiation Exposure Rate of Patients Receiving I-131 Therapy for Hyperthyroidism and Remnant Ablation as Outpatient: An Institutional Experience

  2023influential citation
• Recombinant or endogenous TSH for radioactive iodine therapy in thyroid cancer: state of knowledge and current controversies.

  2023cites this paper
• Effect of recombinant human thyroid stimulating hormone on long-term salivary gland dysfunction in thyroid cancer patients treated with radioactive iodine. A systematic review.

  2023cites this paper
• Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project

  2023cites this paper
• The Nuclear Medicine Patient as a Line Source: The Source Length Is Certainly Not the Patient Height, But It Is a Reasonable Approximation

  2022cites this paper
• Milestones in dosimetry for nuclear medicine therapy

  2022cites this paper
• Recombinant human thyrotropin versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer: Experience in a South Taiwanese medical center

  2022cites this paper
• Radioactive Iodine (131I) Thyroid Ablation and the Salivary Glands

  2022cites this paper
• Feasibility of Recombinant Human TSH as a Preparation for Radioiodine Therapy in Patients with Distant Metastases from Papillary Thyroid Cancer: Comparison of Long-Term Survival Outcomes with Thyroid Hormone Withdrawal

  2022cites this paper
• Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for 131I Administration

  2022cites this paper
• Patient-specific biokinetics and hybrid 2D/3D approach integration in OEDIPE software: Application to radioiodine therapy.

  2022cites this paper
• Initial Evaluation of Therapy Response after Adjuvant Radioiodine Therapy in Patients with Early-Stage Papillary Thyroid Cancer—Does Time Matter?

  2022cites this paper
• Personalized Dosimetry in the Context of Radioiodine Therapy for Differentiated Thyroid Cancer

  2022cites this paper
• Fundamentals of internal radiation dosimetry

  2022cites this paper
• Radioiodine Therapy in Pediatric Differentiated Thyroid Cancer

  2022cites this paper
• From reactor to patient: an example of radioactive diagnostics and effective half-life in thyroid cancer treatment

  2022cites this paper
• Response to “Radioiodine Is Molecular Radiotherapy Governed by Predictable Deterministic Radiobiology Expressed in Gray, Not Millicuries” by Kao

  2022influential citation
• Radio-Iodide Treatment: From Molecular Aspects to the Clinical View

  2021cites this paper
• Outcomes of Thyrotropin Alfa Versus Levothyroxine Withdrawal-Aided Radioiodine Therapy for Distant Metastasis of Papillary Thyroid Cancer

  2021cites this paper
• Adjustment of the iodine ICRP population pharmacokinetic model for the use in thyroid cancer patients after thyroidectomy

  2021cites this paper
• Dependency of the remnant 131I-NaI biokinetics on the administered activity in patients with differentiated thyroid cancer.

  2021cites this paper
• Cytogenetic follow-up studies on humans with internal and external exposure to ionizing radiation

  2021influential citation
• Effect of TSH stimulation protocols on adequacy of low-iodine diet for radioiodine administration

  2021cites this paper
• Whole-Body Radioiodine Effective Half-Life in Patients with Differentiated Thyroid Cancer

  2021cites this paper
• Influence of Levothyroxine with Recombinant Human TSH on Urine Iodine Excretion Before Radioactive Iodine Administration.

  2021cites this paper
• Hypothyroidism in infant of breast feeding mother after Radioiodine therapy (for CA Thyroid): a case report

  2021cites this paper
• A practical individualized radiation precaution based on the dose rate at release time after inpatient 131I ablation therapy

  2021cites this paper
• Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand?

  2021cites this paper
• Top 100 Cited Articles in Thyroid Cancer: A Bibliometric Analysis

  2021cites this paper
• 2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?

  2021cites this paper
• Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice.

  2021cites this paper
• Individualized dosimetry in children and young adults with differentiated thyroid cancer undergoing iodine-131 therapy

  2020cites this paper
• Differentiated Thyroid Cancer, From Active Surveillance to Advanced Therapy: Toward a Personalized Medicine

  2020cites this paper
• Recommendations for Multicentre Clinical Trials Involving Dosimetry for Molecular Radiotherapy

  2020cites this paper
• Multicentre Trials on Standardised Quantitative Imaging and Dosimetry for Radionuclide Therapies.

  2020cites this paper
• Personalized management of differentiated thyroid cancer in real life – practical guidance from a multidisciplinary panel of experts

  2020cites this paper
• Setting up a quantitative SPECT imaging network for a European multi-centre dosimetry study of radioiodine treatment for thyroid cancer as part of the MEDIRAD project

  2020cites this paper
• Red Marrow Absorbed Dose Calculation in Thyroid Cancer Patient Using a Simplified Excel Spreadsheet

  2020cites this paper
• Recommendations for multi-centre clinical trials involving 1 dosimetry for molecular radiotherapy 2

  2020cites this paper
• An indirect high iodine (131I) effective dose used for thyroid ablation in patients with thyroid cancer. Is the method of measurement important?

  2020influential citation
• Radiation exposure to allied health personnel handling blood specimens from patients receiving radioactive iodine-131 and recombinant human TSH (thyrogen®) stimulation

  2020cites this paper
• Eurados review of retrospective dosimetry techniques for internal exposures to ionising radiation and their applications

  2020cites this paper
• Differentiated Thyroid Cancer: Radioiodine Therapy

  2020cites this paper
• Failure of iodine uptake in microscopic pulmonary metastases after recombinant human thyroid-stimulating hormone stimulation

  2020influential citation
• Optimization of serum thyroglobulin measured at different time points for prognostic evaluation in differentiated thyroid carcinoma patients

  2020cites this paper
• Simple variance reduction in Monte Carlo calculations of specific absorbed fractions: Russian roulette and splitting at the source organ

  2020cites this paper
• The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons: Core questions and recommendations for treatments of thyroid cancer.

  2020cites this paper
• Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy.

  2020cites this paper
• Can the basal serum thyroglobulin level be used to predict the recombinant human TSH-stimulated thyroglobulin level in differentiated patients with thyroid cancer?

  2019cites this paper
• Determination and Comparison of Radiation Absorbed dose to the Blood, by Applying Different Techniques, for Patients, Suffering from Differentiated Thyroid Cancer

  2019influential citation
• Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose

  2019cites this paper
• The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer.

  2019cites this paper
• Radioiodine Therapy of Thyroid Cancer

  2019cites this paper
• The Preventive Effect of Parotid Gland Massage on Salivary Gland Dysfunction During High-Dose Radioactive Iodine Therapy for Differentiated Thyroid Cancer: A Randomized Clinical Trial.

  2019cites this paper
• Pediatric Differentiated Thyroid Cancer: Our Experience

  2019cites this paper
• Lesion-Wise Comparison of Pre-Therapy and Post-Therapy Effective Half-Life of Iodine-131 in Pediatric and Young Adult Patients with Differentiated Thyroid Cancer Undergoing Radioiodine Therapy

  2019cites this paper
• Clinical outcomes of patients with T4 or N1b well-differentiated thyroid cancer after different strategies of adjuvant radioiodine therapy

  2019cites this paper
• Initial treatment of pediatric differentiated thyroid cancer: a review of the current risk-adaptive approach

  2019cites this paper
• Analysis of activity uptake, effective half-life and time-integrated activity for low- and high-risk papillary thyroid cancer patients treated with 1.11 GBq and 3.7 GBq of 131I-NaI respectively.

  2019influential citation
• Fast-track Radioiodine Ablation Therapy After Thyroidectomy Reduces Sick Leave in Patients With Differentiated Thyroid Cancer (FASTHYNA Trial)

  2019cites this paper
• ICRP Publication 140: Radiological Protection in Therapy with Radiopharmaceuticals

  2019cites this paper
• Comparison of I-131 Biokinetics after Recombinant Human TSH Stimulation and Thyroid Hormone Withdrawal Measured by External Detector in Patients with Differentiated Thyroid Cancer

  2019cites this paper
• Radioactive Iodine Uptake in Response to Recombinant Human Thyrotropin Stimulation for Thyroid Remnant Ablation in Patients with Differentiated Thyroid Cancer

  2019cites this paper
• [18F]Tetrafluoroborate ([18F]TFB) and its analogs for PET imaging of the sodium/iodide symporter

  2018cites this paper
• Estimation of blood and bone marrow doses of thyroid carcinoma patients treated with 131I through gamma spectrometry

  2018cites this paper
• Langfristige Auswirkungen der Radiojod-Therapie auf das Blutbild bei differenziertem Schilddrüsenkarzinom

  2018cites this paper
• Evaluation of the dosimetry approaches in ablation treatment of thyroid cancer

  2018cites this paper
• Thyroid Uptake and Effective Half-Life of Radioiodine in Thyroid Cancer Patients at Radioiodine Therapy and Follow-Up Whole-Body Scintigraphy Either in Hypothyroidism or Under rhTSH

  2018influential citation
• Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial.

  2018cites this paper
• Determination of effective half-life of 131I in patients with differentiated thyroid carcinoma: comparison of cystatin C and creatinine-based estimation of renal function

  2018cites this paper
• Preferred strategy for postsurgical thyroid ablation in low-risk thyroid cancer.

  2018cites this paper
• Radioiodine Ablation: Current Status

  2018cites this paper
• Pediatric Differentiated Thyroid Carcinoma

  2018cites this paper
• Dosimetric Approaches: Current Concepts

  2018cites this paper
• Quantitative Bildgebung für die Dosimetrie mit SPECT/CT

  2018cites this paper
• Dosimetrie beim Schilddrüsenkarzinom

  2018cites this paper
• Ablative Radioiodtherapie des Schilddrüsenkarzinoms

  2018cites this paper
• PROBLEMATIKA DOZIMETRIE V CÍLENÉ RADIONUKLIDOVÉ TERAPII

  2018influential citation